MX2019010107A - Composicion para administracion intravesical para tratar el dolor en la vejiga. - Google Patents
Composicion para administracion intravesical para tratar el dolor en la vejiga.Info
- Publication number
- MX2019010107A MX2019010107A MX2019010107A MX2019010107A MX2019010107A MX 2019010107 A MX2019010107 A MX 2019010107A MX 2019010107 A MX2019010107 A MX 2019010107A MX 2019010107 A MX2019010107 A MX 2019010107A MX 2019010107 A MX2019010107 A MX 2019010107A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- bladder pain
- intravesical administration
- treating bladder
- administration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se relaciona con una composición farmacéutica que comprende cis-(E)-4-(3-fluorofenil)-2',3',4',9'-tetrahidro-N,N-dim etil-2'-(1-oxo-3-fenil-2-propenil)-spiro[ciclohexano-1,1'[1H]-pir ido[3,4-b]indol]-4-amina. La composición farmacéutica es adecuada para la administración tópica, especialmente para administración intravesical en el tratamiento de dolor en la vejiga.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17020068 | 2017-02-24 | ||
PCT/EP2018/054453 WO2018154028A1 (en) | 2017-02-24 | 2018-02-23 | Composition for intravesical administration for treating bladder pain |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019010107A true MX2019010107A (es) | 2019-11-21 |
Family
ID=58231332
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019010107A MX2019010107A (es) | 2017-02-24 | 2018-02-23 | Composicion para administracion intravesical para tratar el dolor en la vejiga. |
Country Status (11)
Country | Link |
---|---|
US (1) | US20180243273A1 (es) |
EP (1) | EP3585359A1 (es) |
JP (1) | JP2020508332A (es) |
CN (1) | CN110494128A (es) |
AU (1) | AU2018223906A1 (es) |
BR (1) | BR112019016545A2 (es) |
CA (1) | CA3054374A1 (es) |
EA (1) | EA201991960A1 (es) |
MX (1) | MX2019010107A (es) |
TW (1) | TW201832765A (es) |
WO (1) | WO2018154028A1 (es) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020030777A1 (en) * | 2018-08-10 | 2020-02-13 | Grünenthal GmbH | Composition for treating urinary frequency and/or urinary urgency |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI582092B (zh) | 2010-07-28 | 2017-05-11 | 歌林達股份有限公司 | 順式-四氫-螺旋(環己烷-1,1’-吡啶[3,4-b]吲哚)-4-胺-衍生物 |
PT2970284T (pt) * | 2013-03-15 | 2018-02-08 | Gruenenthal Gmbh | Cis-(e)-4-(3-fluorofenil)-2',3',4',9'-tetra-hidro-n,n-dimetil-2'-(1-oxo-3-fenil-2-propenil)-espiro[ciclo-hexano-1,1'[1h]-pirido[3,4-b]indol]-4-amina cristalina |
-
2018
- 2018-02-07 TW TW107104328A patent/TW201832765A/zh unknown
- 2018-02-23 CN CN201880013675.6A patent/CN110494128A/zh active Pending
- 2018-02-23 AU AU2018223906A patent/AU2018223906A1/en not_active Abandoned
- 2018-02-23 BR BR112019016545-2A patent/BR112019016545A2/pt not_active Application Discontinuation
- 2018-02-23 MX MX2019010107A patent/MX2019010107A/es unknown
- 2018-02-23 US US15/903,772 patent/US20180243273A1/en not_active Abandoned
- 2018-02-23 EP EP18707887.8A patent/EP3585359A1/en not_active Withdrawn
- 2018-02-23 JP JP2019546192A patent/JP2020508332A/ja active Pending
- 2018-02-23 WO PCT/EP2018/054453 patent/WO2018154028A1/en unknown
- 2018-02-23 CA CA3054374A patent/CA3054374A1/en not_active Abandoned
- 2018-02-23 EA EA201991960A patent/EA201991960A1/ru unknown
Also Published As
Publication number | Publication date |
---|---|
BR112019016545A2 (pt) | 2020-03-31 |
US20180243273A1 (en) | 2018-08-30 |
JP2020508332A (ja) | 2020-03-19 |
CN110494128A (zh) | 2019-11-22 |
TW201832765A (zh) | 2018-09-16 |
EP3585359A1 (en) | 2020-01-01 |
WO2018154028A1 (en) | 2018-08-30 |
EA201991960A1 (ru) | 2020-01-24 |
AU2018223906A1 (en) | 2019-10-17 |
CA3054374A1 (en) | 2018-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
PH12020500066A1 (en) | Carboxamides as modulators of sodium channels | |
WO2014152029A3 (en) | Oxazolo[5,4-c]quinolin-2-one compounds as bromodomain inhibitors | |
MY188139A (en) | Sodium channel modulators for the treatment of pain | |
SG10201808102WA (en) | Bicyclic heterocycle compounds and their uses in therapy | |
MX2021002321A (es) | Nuevos metodos. | |
WO2016207090A3 (en) | Targeted conjugates of ksp inhibitors | |
SG10201805552PA (en) | Sodium channel modulators for the treatment of pain and diabetes | |
PH12014501963A1 (en) | Inhibitors of beta-secretase | |
SG10201810660QA (en) | Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain | |
CL2008002747A1 (es) | Compuestos derivados de furo y tienopirimidina; composicion farmaceutica; metodo para modular la actividad del receptor de histamina h4; y uso en el tratamiento de trastornos tales como inflamacion, trastornos alergicos, dermatologicos, entre otros. | |
MX356343B (es) | Compuestos que inhiben la exocitosis neuronal (ii). | |
NZ745186A (en) | 8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
MX2018007152A (es) | Uso de estimuladores de guanilato ciclasa soluble (sgc) para el tratamiento de la disfuncion del esfinter gastrointestinal. | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
MX2014001393A (es) | 3-(bifenil-3-il)-4-hidroxi-8-metoxi-1-azaespiro[4.5]dec-3-en-2-on as sustituidas. | |
ZA201805358B (en) | 3-(carboxymethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
MD20150030A2 (ro) | Inhibitori de beta-secretază | |
WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
MX2020006174A (es) | Tratamientos de combinación que comprenden la administración de 1h-pirazol[4,3-b]piridinas. | |
WO2017121646A8 (en) | 3-(carboxyethyl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives | |
MX363200B (es) | Composición odontológica de papaína en gel para el tratamiento atraumático de caries y método para prepararla. | |
EA202190281A1 (ru) | Производные 3-((гетеро-)арил)-8-амино-2-оксо-1,3-диаза-спиро[4,5]декана | |
WO2015048188A8 (en) | Modified fibroblast growth factors for the treatment of ocular disorders | |
WO2018062876A3 (ko) | 통증이 경감되는 골관절염 치료용 키트 |